{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:28:14Z","timestamp":1767968894985,"version":"3.49.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Vitamin D 24-hydroxylase is an enzyme encoded by the CYP24A1 gene, which inhibits the activation of vitamin D to form inactive metabolites. More than 20 currently described pathogenic variants (usually biallelic) of this gene are responsible for idiopathic infantile hypercalcemia manifested typically in childhood (often in newborns) with hypercalcemia, hypercalciuria, and nephrocalcinosis. However, a few patients (mostly with monoallelic heterozygous pathogenic variants) can develop mild symptoms in adulthood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case description<\/jats:title><jats:p>We present the case of a 43-year-old male patient with hypertension and heterozygous Leiden mutation, with mural thrombi in the common iliac artery, who was sent by a nephrologist to endocrinological examination due to hypoparathyroidism, progressive hypercalcemia, hypercalciuria, and CKDG2A1. Complete laboratory and imaging methods (including PET-CT) excluded PTH-related peptide-mediated hypercalcemia and granulomatosis. Finally, the genetic analysis of the CYP24A1 gene revealed the presence of a novel combination of two heterozygous pathogenic variants: CYP24A1: c. 443T&amp;gt;C p.(Leu148Pro) and c.1186C&amp;gt;T p.(Arg396Trp).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Differential diagnosis of patients with hypercalciuria, nephrocalcinosis, and hypercalcemia related to vitamin D exposure should include the CYP24A1 gene mutation. To the best of our knowledge, this is the first case of the novel combination of two heterozygous pathogenic variants of CYP24A1.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.1020096","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T20:13:14Z","timestamp":1673381594000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: Two heterozygous pathogenic variants of CYP24A1: A novel cause of hypercalcemia and nephrocalcinosis in adulthood"],"prefix":"10.3389","volume":"9","author":[{"given":"Ludmila","family":"Brunerova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ondrej","family":"Remes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Zoubkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Votypka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/B978-0-12-416015-6.00013-7","article-title":"Chapter 13 - calcium and phosphate: hormonal regulation and metabolism","volume-title":"Basic and Applied Bone Biology","author":"DiMeglio","year":"2014"},{"key":"B2","first-page":"1959","article-title":"A practical approach to hypercalcemia","volume":"67","author":"Carroll","year":"2003","journal-title":"Am Fam Physician."},{"key":"B3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1056\/NEJMoa1103864","article-title":"Mutations in CYP24A1 and idiopathic infantile hypercalcemia","volume":"365","author":"Schlingmann","year":"2011","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jsbmb.2017.01.006","article-title":"CYP24A1 loss of function: Clinical phenotype of monoallelic and biallelic mutations","volume":"173","author":"Carpenter","year":"2017","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1515\/cclm-2018-1208","article-title":"CYP24A1 and SLC34A1 genetic defects associated with idiopathic infantile hypercalcemia: from genotype to phenotype","volume":"57","author":"De Paolis","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1007\/s00198-016-3615-6","article-title":"Clinical and biochemical phenotypes of adults with monoallelic and biallelic CYP24A1 mutations: evidence of gene dose effect","volume":"27","author":"O'Keeffe","year":"2016","journal-title":"Osteoporosis Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(53)90187-1","article-title":"Idiopathic hypercalcaemia in infants","volume":"262","author":"Lightwood","year":"1953","journal-title":"Lancet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1210\/jc.2013-3802","article-title":"A lifetime of hypercalcemia and hypercalciuria, finally explained","volume":"99","author":"Jacobs","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.ecl.2017.07.011","article-title":"Genetic diseases of vitamin D metabolizing enzymes","volume":"46","author":"Jones","year":"2017","journal-title":"Endocrinol Metab Clin North Am."},{"key":"B10","doi-asserted-by":"publisher","first-page":"E1343","DOI":"10.1210\/jc.2014-4387","article-title":"CYP24A1 mutations in a cohort of hypercalcemic patients: evidence for a recessive trait","volume":"100","author":"Molin","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4982621","DOI":"10.1155\/2019\/4982621","article-title":"Hereditary hypercalcemia caused by a homozygous pathogenic variant in the CYP24A1 gene: a case report and review of the literature","volume":"2019","author":"Cappellani","year":"2019","journal-title":"Case Rep Endocrinol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1210\/clinem\/dgab431","article-title":"Mild idiopathic infantile hypercalcemia-part 1: biochemical and genetic findings","volume":"106","author":"Lenherr-Taube","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"key":"B14","doi-asserted-by":"publisher","first-page":"736240","DOI":"10.3389\/fendo.2021.736240","article-title":"overlapping phenotypes associated with CYP24A1, SLC34A1, and SLC34A3 mutations: a cohort study of patients with hypersensitivity to vitamin D","volume":"12","author":"Molin","year":"2021","journal-title":"Front Endocrinol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2215\/CJN.05360512","article-title":"1,25-(OH)2D-24 hydroxylase (CYP24A1) deficiency as a cause of nephrolithiasis","volume":"8","author":"Nesterova","year":"2013","journal-title":"Clin J Am Soc Nephrol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.abb.2011.11.003","article-title":"25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D","volume":"523","author":"Jones","year":"2012","journal-title":"Arch Biochem Biophys."},{"key":"B17","doi-asserted-by":"publisher","first-page":"28729","DOI":"10.1074\/jbc.M111.236679","article-title":"Bioengineering anabolic vitamin D-25-hydroxylase activity into the human vitamin D catabolic enzyme, cytochrome P450 CYP24A1, by a V391L mutation","volume":"286","author":"Kaufmann","year":"2011","journal-title":"J Biol Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00431-012-1818-1","article-title":"Severe hypercalcemic crisis in an infant with idiopathic infantile hypercalcemia caused by mutation in CYP24A1 gene","volume":"172","author":"Fencl","year":"2013","journal-title":"Eur J Pediatr."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.4158\/EP13479.CR","article-title":"A case of \u201clate-onset\u201d idiopathic infantile hypercalcemia secondary to mutations in the CYP24A1 gene","volume":"20","author":"Wolf","year":"2014","journal-title":"Endocr Pract."},{"key":"B20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00467-014-2889-1","article-title":"Maternal and infantile hypercalcemia caused by vitamin-D-hydroxylase mutations and vitamin D intake","volume":"30","author":"Dinour","year":"2015","journal-title":"Pediatr Nephrol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1053\/j.ajkd.2014.06.037","article-title":"Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations","volume":"65","author":"Figueres","year":"2015","journal-title":"Am J Kidney Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1210\/jc.2015-1973","article-title":"Maternal hypercalcemia due to failure of 1,25-dihydroxyvitamin-D3 catabolism in a patient with CYP24A1 mutations","volume":"100","author":"Shah","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bone.2015.06.018","article-title":"Calcium and bone homeostasis in heterozygous carriers of CYP24A1 mutations: a cross-sectional study","volume":"81","author":"Cools","year":"2015","journal-title":"Bone"},{"key":"B24","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1159\/000500922","article-title":"Novel CYP24A1 mutation in a young male patient with nephrolithiasis: case report","volume":"44","author":"Jir\u00e1\u010dkov\u00e1","year":"2019","journal-title":"Kidney Blood Press Res."},{"key":"B25","first-page":"160","article-title":"Intravenous pamidronate in the treatment of severe idiopathic infantile hypercalcemia","volume":"7","author":"Skalova","year":"2013","journal-title":"Iran J Kidney Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1210\/endo.141.7.7579","article-title":"Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D","volume":"141","author":"St-Arnaud","year":"2000","journal-title":"Endocrinology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/ndt\/gft460","article-title":"Chronic hypercalcaemia from inactivating mutations of vitamin D 24-hydroxylase (CYP24A1): Implications for mineral metabolism changes in chronic renal failure","volume":"29","author":"Colussi","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B28","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jsbmb.2010.02.002","article-title":"CYP24A1-deficient mice as a tool to uncover a biological activity for vitamin D metabolites hydroxylated at position 24","volume":"121","author":"St-Arnaud","year":"2010","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jpeds.2010.02.025s","article-title":"Infantile hypercalcemia and hypercalciuria: new insights into a vitamin D-dependent mechanism and response to ketoconazole treatment","volume":"157","author":"Nguyen","year":"2010","journal-title":"J Pediatr"},{"key":"B30","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/ckj\/sfv028","article-title":"Successful treatment of hypercalcaemia associated with a CYP24A1 mutation with fluconazole","volume":"8","author":"Sayers","year":"2015","journal-title":"Clin Kidney J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"E423","DOI":"10.1210\/jc.2011-1935","article-title":"Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy","volume":"97","author":"Tebben","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1210\/jc.2016-4048","article-title":"CYP3A4 Induction by Rifampin: an alternative pathway for Vitamin D inactivation in patients with CYP24A1 mutations","volume":"102","author":"Hawkes","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.urology.2016.08.007","article-title":"Effect of L-methionine on the risk of phosphate stone formation","volume":"98","author":"Siener","year":"2016","journal-title":"Urology."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1020096\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T20:13:22Z","timestamp":1673381602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1020096\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":33,"alternative-id":["10.3389\/fmed.2022.1020096"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1020096","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]},"article-number":"1020096"}}